Journal article
The role of asymmetric dimethylarginine alone and in combination with N-terminal pro-B-type natriuretic peptide as a screening biomarker for systemic sclerosis-related pulmonary arterial hypertension: A case control study
V Thakkar, W Stevens, D Prior, C Rabusa, J Sahhar, J G.Walker, J Roddy, S Lester, M Rischmueller, J Zochling, P Nash, E Gabbay, P Youssef, SM Proudman, M Nikpour
Clinical and Experimental Rheumatology | CLINICAL & EXPER RHEUMATOLOGY | Published : 2016
Abstract
Objective. Asymmetric dimethylarginine (ADMA) is a novel biomarker of endothelial cell dysfunction. In this proof of concept study, we sought to evaluate the role of ADMA as a screening biomarker for incident systemic sclerosis-related pulmonary arterial hypertension (SSc-PAH). Methods. ADMA levels were measured using high performance liquid chromatography in 15 consecutive treatment-naive patients with newly-diagnosed SSc-PAH and compared with 30 SSc-controls without PAH. Logistic regression models were used to evaluate the independent association of ADMA with PAH. The optimal cut-point of ADMA for SSc-PAH screening was determined. NT-proBNP levels were previously measured in the same patie..
View full abstract